doi: 10.1016/s0021-9673(00)85018-9.
Quantitative assay of sulphinpyrazone in plasma and urine by high-performance liquid chromatography
- PMID: 932142
- DOI: 10.1016/s0021-9673(00)85018-9
Item in Clipboard
Quantitative assay of sulphinpyrazone in plasma and urine by high-performance liquid chromatography
J Chromatogr.
.
Abstract
A method for the quantitative determination of sulphinpyrazone in plasma and urine is described. The drug is extracted from the acidified aqueous phase with 1-chlorobutane-ethylene dichloride (4:1) and separated from its metabolites by high-performance liquid chromatography on 5-mum LiChrosorb using dichloromethane-ethanol-water-acetic acid (79.1:19:1.9:0.002) as the mobile phase. The sensitivity limit is 0,2mug/ml using a 1-ml sample. Examples of applications are given.
Similar articles
-
Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.Pharm Weekbl Sci. 1985 Dec 13;7(6):252-9. doi: 10.1007/BF01959198. Pharm Weekbl Sci. 1985. PMID: 4080510
-
High-performance liquid chromatographic analysis of sulfinpyrazone and its metabolites in biological fluids.J Chromatogr. 1980 Mar 14;181(3-4):417-25. doi: 10.1016/s0378-4347(00)81144-5. J Chromatogr. 1980. PMID: 7391155
-
Analysis of sulfinpyrazone and its metabolites in human plasma and urine by high-performance liquid chromatography.J Chromatogr. 1983 Oct 14;277:408-13. doi: 10.1016/s0378-4347(00)84867-7. J Chromatogr. 1983. PMID: 6643630 No abstract available.
-
High-performance liquid chromatographic determination of sulfinpyrazone and its metabolites in plasma.Arzneimittelforschung. 1984;34(5):548-50. Arzneimittelforschung. 1984. PMID: 6540568
-
Simple and rapid micro-determination of sulfinpyrazone (Anturan) in biological fluids by reversed-phase high-performance liquid chromatography.J Chromatogr. 1978 Mar 21;150(2):521-6. doi: 10.1016/s0021-9673(00)88214-x. J Chromatogr. 1978. PMID: 632338 No abstract available.
Cited by
-
Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone.Clin Pharmacokinet. 1982 Jan-Feb;7(1):42-56. doi: 10.2165/00003088-198207010-00003. Clin Pharmacokinet. 1982. PMID: 7042172 Review. No abstract available.
-
Plasma levels and pharmacokinetics of sulphinpyrazone in renal impairment during chronic treatment: a case report.Br J Clin Pharmacol. 1984 Jul;18(1):107-8. doi: 10.1111/j.1365-2125.1984.tb05033.x. Br J Clin Pharmacol. 1984. PMID: 6743484 Free PMC article. No abstract available.
-
Determination of sulfinpyrazone and four metabolites in plasma and urine by high pressure liquid chromatography.Pharm Weekbl Sci. 1985 Dec 13;7(6):252-9. doi: 10.1007/BF01959198. Pharm Weekbl Sci. 1985. PMID: 4080510
-
Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist.J Clin Invest. 1980 Nov;66(5):884-91. doi: 10.1172/JCI109955. J Clin Invest. 1980. PMID: 7430350 Free PMC article.
-
Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.Br J Clin Pharmacol. 1982 Feb;13(2):177-85. doi: 10.1111/j.1365-2125.1982.tb01353.x. Br J Clin Pharmacol. 1982. PMID: 7059415 Free PMC article.